Clinical Trials Logo

Relapsed Plasmablastic Lymphoma clinical trials

View clinical trials related to Relapsed Plasmablastic Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04676360 Recruiting - Clinical trials for Refractory Plasmablastic Lymphoma

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. - This research study involves the study drug belantamab mafodotin. - Belantamab mafodotin is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a drug. It works by using the antibody portion to enter into the lymphoma cells, and then releasing the drug portion to kill the lymphoma cells.